Legato Capital Management LLC Makes New $835,000 Investment in Dyne Therapeutics, Inc. $DYN

Legato Capital Management LLC acquired a new stake in Dyne Therapeutics, Inc. (NASDAQ:DYN) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 42,665 shares of the company’s stock, valued at approximately $835,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Axxcess Wealth Management LLC purchased a new position in shares of Dyne Therapeutics in the fourth quarter valued at approximately $2,234,000. PSP Research LLC purchased a new position in shares of Dyne Therapeutics in the fourth quarter valued at approximately $421,000. Profund Advisors LLC boosted its stake in shares of Dyne Therapeutics by 88.7% in the fourth quarter. Profund Advisors LLC now owns 86,746 shares of the company’s stock valued at $1,697,000 after purchasing an additional 40,766 shares during the period. ProShare Advisors LLC boosted its stake in shares of Dyne Therapeutics by 21.8% in the fourth quarter. ProShare Advisors LLC now owns 28,926 shares of the company’s stock valued at $566,000 after purchasing an additional 5,185 shares during the period. Finally, Strs Ohio purchased a new position in Dyne Therapeutics in the fourth quarter worth approximately $51,000. Hedge funds and other institutional investors own 96.68% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on DYN shares. Wall Street Zen upgraded shares of Dyne Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 16th. HC Wainwright cut their target price on shares of Dyne Therapeutics from $60.00 to $50.00 and set a “buy” rating on the stock in a report on Tuesday, March 3rd. Jefferies Financial Group reaffirmed a “buy” rating on shares of Dyne Therapeutics in a report on Monday, March 9th. Sanford C. Bernstein boosted their price objective on shares of Dyne Therapeutics from $23.00 to $24.00 and gave the company a “market perform” rating in a research note on Wednesday, May 13th. Finally, Evercore set a $33.00 price objective on shares of Dyne Therapeutics in a research note on Friday, May 15th. Three research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $35.00.

Insider Activity at Dyne Therapeutics

In other news, Director Jason P. Rhodes sold 287,956 shares of the company’s stock in a transaction dated Wednesday, April 22nd. The shares were sold at an average price of $19.68, for a total transaction of $5,666,974.08. Following the completion of the transaction, the director owned 11,663 shares of the company’s stock, valued at $229,527.84. This represents a 96.11% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 1,559,462 shares of company stock worth $29,814,746. Corporate insiders own 14.14% of the company’s stock.

Dyne Therapeutics Price Performance

Dyne Therapeutics stock opened at $17.37 on Tuesday. The firm has a market capitalization of $2.87 billion, a PE ratio of -5.39 and a beta of 1.08. The company has a quick ratio of 19.92, a current ratio of 19.92 and a debt-to-equity ratio of 0.17. The firm’s 50-day simple moving average is $18.27 and its 200 day simple moving average is $18.33. Dyne Therapeutics, Inc. has a 52 week low of $8.06 and a 52 week high of $25.00.

Dyne Therapeutics (NASDAQ:DYN) last released its earnings results on Monday, May 11th. The company reported ($0.73) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.77) by $0.04. During the same quarter in the previous year, the business earned ($1.05) earnings per share. On average, equities research analysts predict that Dyne Therapeutics, Inc. will post -2.99 EPS for the current fiscal year.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.